Skip to main content

Grunenthal Group Taps Dotmatics Software for Drug Data Management, Analysis

Premium

Dotmatics said this week that Grunenthal Group, a German pharmaceutical company, has licensed its software to manage and analyze chemical and biological data in its projects.

Specifically, Grunenthal will use Vortex, an analytics platform that offers tools for creating and manipulating plots, calculating properties as well as profiling compounds; and Browser, which lets users query and visualize their data.

Henning Steinhagen, senior vice president of Grunenthal's global drug discovery arm, said in a statement that his firm selected Dotmatics' products because they provided "optimal support" for querying, reporting, and analyzing drug-related data. Also, Dotmatics' platform "proved to be the most flexible solution for supporting our multidisciplinary project teams," he said.

The financial details of the licensing agreement were not disclosed.

Other recent licensees of Dotmatics' platform for drug discovery purposes include the University of Leeds (BI 2/15/2013); and the Institute of Cancer Research, London (BI 9/21/2012).

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.